论著

强脉冲光治疗睑板腺功能障碍性干眼的临床观察

Clinical study of intense pulse light on meibomian gland dysfunction dry eye

:277-281
 
目的:观察强脉冲光(intense pulse light,IPL)治疗睑板腺功能障碍(meibomian gland dysfunction,MGD)性干眼的临床效果。方法:选取2019年10月至2019年12月在东莞市东南部中心医院眼科门诊就诊的MGD性干眼患者64例(64只右眼),随机分为对照组与观察组,每组32例。对照组采用睑板腺按摩联合常规药物治疗,观察组采用IPL联合睑板腺按摩及常规药物治疗,两组疗程均为6周;观察两组患者治疗前后干眼症状、体征及睑板腺功能变化。结果:治疗后两组干眼症状、体征及睑板腺功能均较治疗前明显改善,差异有统计学意义(P>0.05);观察组治疗后2、4周干眼症状、体征及睑板腺功能评分改善优于对照组,差异有统计学意义(P<0.05);治疗后6周两组各项观察指标差异无统计学意义(P>0.05)。经过6周治疗,观察组有效率为87.5%(28/32),对照组有效率75%(24/32),差异有统计学意义(P=0.021)。治疗期间两组均未发生不良反应。结论:IPL联合睑板腺按摩对MGD性干眼能有效减轻眼部不适症状、改善睑板腺功能,较单纯睑板腺按摩起效更快、效果更佳。
Objective: To observe the clinical effect of intense pulse light (IPL) on MGD dry eyes. Methods: Sixty-four patients(64 right eyes) with MGD dry eye from October 2019 to December 2019 were collected and randomly divided into control group (n=32) and observation group (n=32). The control group was treated with meibomian gland massage combined with conventional medicine, while the observation group was treated with IPL combined with meibomian gland massage and conventional medicine. The course of treatment of both groups was 6 weeks. The dry eye symptoms, dry eye signs and meibomian gland function changes were observed before and after treatment in both groups. Results: The dry eye symptoms, physical signs and meibomian gland function of the two groups after treatment were significantly improved compared with those before treatment (P>0.05). The improvement of dry eye  symptoms, physical signs and meibomian gland function in observation group were better than those of the control group at two and four weeks after treatment (P<0.05), while there was no statistically significant difference between the two groups at 6 weeks after treatment (P>0.05). The effective rate in observation group was 87.5% (28/32) after 6 weeks treatment, while control group was 75% (24/32), the difference was statistically significant (P=0.021). No adverse reactions occurred in both groups during the treatment. Conclusion: IPL combined with meibomian gland massage can effectively reduce the ocular discomfort and improve the function of meibomian gland in MGD dry eyes,which is faster and more effective than meibomian gland massage alone.
综述

青光眼睫状体炎综合征病因及治疗的研究进展

Research progress in etiology and treatment of Posner-Schlossman syndrome

:998-1005
 
青光眼睫状体炎综合征(Posner-Schlossman syndrome,PSS)表现为单眼反复发作性非肉芽肿性前葡萄膜炎,伴有眼压升高,可发展为慢性继发性青光眼,最终导致视神经损伤。尽管PSS总体预后良好,但仍有部分患者因反复眼压骤升造成视神经损伤持续进展,甚至导致失明。目前,PSS的确切病因尚不明确,治疗方式以控制炎症及眼压为主。本文将从病因及治疗两方面阐述PSS的研究现状,以期为PSS相关基础研究及临床诊治提供思路及参考。
Posner-Schlossman syndrome (PSS), also called glaucomatocyclitic crisis, is characterized by recurrent non-granulomatous anterior uveitis, accompanied by elevated intraocular pressure. It is able to develop into chronic secondary glaucoma and eventually lead to optic nerve injury. Although the overall prognosis of PSS is favourable, there are still some patients whose optic nerve injury continues to progress and even lead to blindness due to recurrent attacks of ocular hypertension. At present, the exact cause of PSS is not clear, and the treatment is mainly to control inflammation and intraocular pressure. This article will elaborate the research status of PSS from two aspects of etiology and treatment to provide ideas and reference for the basic research clinical diagnosis and treatment of PSS.
近视防控专栏

人工智能在近视防控与治疗中的应用进展

Advances in the application of artificial intelligence in the prevention, control and treatment of myopia

:965-971
 
近视是危害儿童青少年视力最常见的眼部疾病,高度近视对视功能造成极大的威胁。近年来,我国近视发病率逐年升高,对近视筛查与防控的需求也不断增加,随着人工智能理论与技术的不断发展与成熟,可以辅助眼科医生进行近视筛查、诊断与治疗。本文将简要介绍人工智能在近视的筛查、预测、检测、病理性近视以及角膜屈光手术中的应用,浅谈了目前人工智能在研究中存在的可比度较低、影像要求较高、可解释性较低及隐私保护等问题,并展望人工智能在近视相关领域的应用前景。
Myopia is the most common ocular disease that harms the vision of children and adolescents. High myopia poses a great threat to visual function. The incidence of myopia in China has been increasing in recent years, and the demand for myopia screening, prevention and control has also expanded. With the continuous development of artificial intelligence theory and technology, Artificial intelligence can assist ophthalmologists in myopia screening, diagnosis and treatment. This review will briefly introduce artificial intelligence in the screening, prediction, and detection of myopia; also, the application in pathological myopia and corneal refractive surgery. This review will discuss some problems of current artificial intelligence research, such as low comparability, high image requirements, low interpretability, privacy protection, and the application prospects of artificial intelligence in myopia.
近视防控专栏

儿童圆锥角膜的治疗新进展

New progress in the treatment of pediatric keratoconus

:959-964
 
目前对于成人圆锥角膜(keratoconus,KC)的研究已经很广泛,而对于儿童KC的研究则较少,其诊断和治疗常常基于成人KC的研究基础。与成人KC相比,儿童KC的发展更迅速、造成的后果更严重,其导致的儿童视觉障碍会追随其一生,对其生活质量以及教育发展产生严重的负面影响。为了对儿童KC的治疗有较全面的认识和理解,本文针对近几年儿童KC的治疗进展,对不同治疗方法的安全性、有效性和治疗时机等方面进行综述。
At present, the research on adult keratoconus has been extensive, while the research on pediatric keratoconus is few. The diagnosis and treatment of pediatric keratoconus are often based on the study of keratoconus in adults. Pediatric keratoconus is more aggressive than adult keratoconus, resulting in visual impairment that can follow throughout their lives and have a serious negative impact on their quality of life and educational development. In this paper, according to the treatment progress of pediatric keratoconus in recent years, the safety, effectiveness, and treatment timing of different treatment methods were summarized, in order to have a more comprehensive understanding of the treatment of pediatric keratoconus.
近视防控专栏

儿童圆锥角膜的治疗新进展

New progress in the treatment of pediatric keratoconus

:-
 
目前对于成人圆锥角膜(keratoconus,KC)的研究已经很广泛,而对于儿童KC的研究则较少,其诊断和治疗常常基于成人KC的研究基础。与成人KC相比,儿童KC的发展更迅速、造成的后果更严重,其导致的儿童视觉障碍会追随其一生,对其生活质量以及教育发展产生严重的负面影响。为了对儿童KC的治疗有较全面的认识和理解,本文针对近几年儿童KC的治疗进展,对不同治疗方法的安全性、有效性和治疗时机等方面进行综述。
At present, the research on adult keratoconus has been extensive, while the research on pediatric keratoconus is few. The diagnosis and treatment of pediatric keratoconus are often based on the study of keratoconus in adults. Pediatric keratoconus is more aggressive than adult keratoconus, resulting in visual impairment that can follow throughout their lives and have a serious negative impact on their quality of life and educational development. In this paper, according to the treatment progress of pediatric keratoconus in recent years, the safety, effectiveness,and treatment timing of different treatment methods were summarized, in order to have a more comprehensive understanding of the treatment of pediatric keratoconus.
论著

二甲双胍治疗与2型糖尿病患者糖尿病性视网膜病变的相关性研究

Relationship between metformin treatment and diabetic retinopathy in patients with type 2 diabetes mellitus

:298-306
 
目的:探讨2型糖尿病(type 2 diabetes mellitus,T2DM)患者二甲双胍治疗与糖尿病性视网膜病变(diabetic retinopathy,DR)的相关性。方法:回顾2015年9月至2020年8月在中日友好医院眼科就诊的1 891例T2DM患者的临床资料,对病程≥10年的324例T2DM患者的一般资料、内科疾病史、糖尿病治疗史、眼科检查和实验室血生化指标进行回顾性病例研究。根据是否接受二甲双胍治疗分为二甲双胍治疗组与非二甲双胍治疗组,根据眼底检查结果同时结合DR临床诊断标准,将DR分为无明显DR、非增生性DR及增生性DR。采用logistic多因素回归分析判断年龄、性别、糖尿病发病年龄、糖尿病病程、高血压病程、高血脂病程、吸烟年数、体重指数、胰岛素治疗及空腹血糖、糖化血红蛋白、总胆固醇、三酰甘油、尿酸和血肌酐水平对结局变量的影响。结果:在DR的发病风险方面,二甲双胍治疗组与非二甲双胍治疗组的差异无统计学意义(P>0.05)。对T2DM患者DR发生及不同分期的相关变量行单因素及多因素分析,结果显示吸烟年数、空腹血糖及肌酐均与DR发病呈正相关(均P<0.05),而年龄与DR发病呈负相关(P<0.01),糖尿病发病年龄与DR发生呈显著负相关(OR=0.95,95%CI:0.92~0.98,P=0.0003)。在二甲双胍治疗的T2DM患者中,二甲双胍的疗程(OR=1.02,95%CI:0.96~1.08,P>0.05)及平均剂量(OR=1.50,95%CI:0.79~2.84,P>0.05)与DR的发生与进展均无显著相关性;女性DR发生与进展的风险较男性低(P<0.05);合并胰岛素治疗与DR发生呈明显正相关(OR=3.11,95%CI:1.59~6.07,P<0.01);吸烟年数长、糖化血红蛋白及尿酸水平高于正常范围均与DR的发生与进展呈正相关(P<0.05)。在口服二甲双胍患者中,未使用胰岛素治疗组和联合使用胰岛素组的DR发病风险有显著差异(P<0.01);而未口服二甲双胍患者中,胰岛素治疗与DR发生呈正相关(OR=12.43,95%CI:3.75~41.19,P<0.0001)。结论:病程10年以上T2DM患者中,二甲双胍治疗与DR发生与进展均无显著相关性。
Objective: To investigate the correlation between metformin therapy and diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM). Methods: The clinical data of 1 891 patients with type 2 diabetes mellitus attending the ophthalmology department of China-Japan Friendship Hospital from September 2015 to August 2020 were reviewed. A retrospective study was performed on 324 cases of these T2DM patients with disease duration ≥10 years. Medical records of all patients including general information, history of medical disease, diabetes treatment, ophthalmologic examination and blood biochemical indices were collected. According to whether metformin treatment was received or not, the patients were divided into a metformin-treated and a non-metformin-treated groups. DR is classified into non-obvious DR, non-proliferative DR and proliferative DR according to the fundus examination and the clinical diagnostic criteria of DR. Logistic multiple regression analysis was used to determine the effects of age, sex, age of DM onset, duration of DM, duration of hypertension,
duration of hyperlipidemia, years of smoking, body mass index, insulin treatment and fasting glucose, glycated hemoglobin, total cholesterol, triglycerides, uric acid and blood creatinine levels on DR. Results: There was no statistically significant difference in the risk of developing DR between the metformin-treated and non-metformin-treated groups (P>0.05). Univariate and multifactorial analyses of variables related to the occurrence and different stages of DR in patients with T2DM showed that years of smoking, fasting glucose and creatinine were positively associated with DR (P<0.05), while age was negatively associated with DR (P<0.01), and age of DM onset was significantly negatively associated with DR (OR=0.95, 95%CI: 0.92 to 0.98, P=0.0003). In T2DM patients treated with metformin, neither the duration of metformin (OR=1.02, 95%CI: 0.96 to 1.08, P>0.05) nor the mean dose(OR=1.50, 95%CI: 0.79 to 2.84, P>0.05) was significantly associated with developing DR. The risk of developing DR was lower in women than in men (P<0.05); combined insulin therapy was significantly positively correlated with the risk of DR (OR=3.11, 95%CI: 1.59 to 6.07, P<0.01); long-term smoking, glycosylated hemoglobin and uric acid levels higher than normal were positively associated with DR (P<0.05). In metformin users, there was a significant difference in the risk of developing DR between the no-insulin treatment group and the combined insulin group (P<0.01); and among patients not using metformin, insulin therapy was positively associated with the occurrence of DR (OR=12.43, 95%CI: 3.75 to 41.19, P<0.0001). Conclusion: There was no significant association between metformin treatment and DR among patients with T2DM for >10 years.
“眼科再生医学”专题

干细胞治疗在角膜重建中的研究进展

Research progress of stem cell therapy in corneal reconstruction

:544-549
 
外伤、感染、先天性疾病等均可能破坏角膜的组织结构和细胞稳态,同时造成角膜干细胞缺损,进而导致组织无法正常愈合,引起角膜盲,是世界范围内致盲的重要原因之一。目前已有多种干细胞相关的技术方法应用于重建功能性角膜组织,取得了瞩目的治疗效果。本综述以角膜缘干细胞缺乏症为主,旨在介绍多种来源的干细胞在角膜重建中的研究现状和最新进展,同时对不同干细胞的特异性标志物的研究进展进行阐述。
Trauma, infection and congenital diseases may disrupt the tissue structure and cellular homeostasis of the cornea, while causing impaired function of corneal stem cell defects, which in turn may even lead to corneal blindness caused by the inability of the tissue to heal properly. Corneal blindness is one of the major causes of blindness worldwide. Several stem cell-related techniques have been applied to reconstruct functional corneal tissue with impressive therapeutic results. This review focuses on corneal limbal stem cell deficiency and aims to present the current status and recent progress of research on stem cells from multiple sources in corneal reconstruction, as well as to describe specific markers of corneal stem cells.
“筑梦·铸人”专题

玻璃体腔注射抗VEGF药物治疗湿性年龄相关性黄斑变性的5年回顾性研究

Intravitreal injection of anti-VEGF agents in wet age-related macular degeneration: a 5-year retrospective study

:537-543
 
目的:调查抗VEGF药物治疗湿性年龄相关性黄斑变性(wet age-related macular degeneration, wAMD)5年的疗效。方法:2011年至2021年于北京医院眼科诊断为wAMD的患者共84人103只眼进行回顾性分析。抗VEGF治疗采用3+PRN方案。观察5年来的最佳矫正视力(best-corrected visual acuity,BCVA)、玻璃体腔注射次数、随访次数和病灶的解剖学变化。结果:治疗5年后平均BCVA为38.1个字母,与基线相比下降9.4个字母,差异有统计学意义(P<0.001)。23.3%的患眼5年后可维持初始视力。5年内平均注射次数为13.8次,第1年注射次数最多,平均为4.3次。5年内平均随访次数为24.3次,仅有34.0%的患眼可遵循每次随访间隔≤3个月。5年后有68.0%的患眼出现纤维瘢痕,27.2%的患眼出现地图样萎缩,69.0%(71/103)的患眼存在持续的色素上皮脱离(pigment epithelial detachment,PED)。年龄、基线BCVA、是否初始治疗、随访年限、注射次数、中心视网膜厚度 (central retina thickness,CRT)、地图样萎缩等对BCVA有显著影响。结论:多数患者在抗VEGF治疗1年内可维持视力,但5年以上维持效果不佳。早期诊治、提高注射频率,可能是未来改善预后的研究方向。
Objective:To investigate the efficacy of anti-VEGF injection in the treatment of wet age-related macular degeneration (wAMD) for 5 years. Methods: A total of 84 patients (103 eyes) wAMD diagnosed in Department of Ophthalmology in Beijing Hospital from 2011 to 2021 were analyzed retrospectively. 3 + PRN regimen was applied for anti-VEGF treatment. The changes of best corrected visual acuity (BCVA), the number of intravitreal injections and the number of follow-up visits, and the anatomical changes of the lesions in the past 5 years were collected. Results: The average BCVA after 5 years was 38.1 letters, indicating a decrease of 9.4 letters comparing to baseline, which was statistically significant (P<0.001). 23.3% of the eyes could maintain the baseline BCVA after 5 years. The average injection times within 5 years was 13.8, and the injection was concentrated in the first year, with an average of 4.3. The average number of follow-up visits within 5 years was 24.3, and only 34.0% of the affected eyes could keep the follow-up interval ≤3 months. After 5 years, 68.0% of the eyes developed fibrous scar, 27.2% developed geographic atrophy, and 69.0% (71/103) had consistent pigment epithelial detachment. Factors significantly affect BCVA include: age, baseline BCVA, initial treatment, follow-up time, injection times, central retinal thickness, geographic atrophy and so on. Conclusion: Most patients can maintain vision within the first year after anti-VEGF treatment, but the efficacy is poor for more than 5 years. Early diagnosis and treatment, and increased injection frequency may be the research direction for improving prognosis in the future.
专家述评

高度重视眶尖部小肿瘤的正确诊断与合理治疗

High attention on the appropriate diagnosis and treatment of small orbital apical tumors

:843-848
 
眶尖部肿瘤为眼科罕见疾病,但因其所处位置特殊,对机体,特别是视神经功能危害极大,错误的诊断、不规范合理的治疗不仅不能解决问题,甚至会对机体造成严重的不可挽回的损害。目前针对眶尖部肿瘤的诊断、治疗多建立在医生的主观认知与经验的基础上,尚未达成共识。本文通过分析眶尖部肿瘤的临床特点,结合以往漏诊、误诊、误治的临床案例,阐述眶尖肿瘤正确诊断的关键要点;同时,结合不同临床案例,客观分析治疗方案,尤其是手术方式、路径,为眶尖部肿瘤的合理化治疗提供依据,以期规范眶尖部肿瘤的诊断和治疗,提高治疗成功率。
Although orbital apical tumor is a rare ophthalmic disease, its special location can cause great harm to the body, especially to the function of the optic nerve. Misdiagnosis and improper treatment are not only unable to solve the problem, but also irretrievably harmful to the body. At present, there is no consensus on the diagnosis and treatment of orbital apical tumors, which are mostly based on subjective cognition and experience of doctors. In this paper, the clinical characters of orbital apical tumors were analyzed through the past clinical cases of misdiagnosis and mistreatment, and the key points of proper diagnosis of orbital apical tumors were expounded. Meanwhile, by combining with different clinical cases, the treatment plans, especially the surgical approaches, were analysed to provide a basis for the appropriate treatment of orbital apical tumors, in order to standardize the diagnosis and treatment of orbital apex tumor, and improve the success rate of treatment.
综述

息肉状脉络膜血管病变继发玻璃体积血的治疗及预后

Treatment modalities and visual prognosis of polypoidal choroidal vasculopathy with breakthrough vitreous hemorrhage

:658-664
 
息肉状脉络膜血管病变(polypoidal choroidal vasculopathy,PCV)是亚洲人中常见的眼底致盲性疾病,当PCV合并视网膜下出血或玻璃体积血(vitreous hemorrhage,VH)时,患者视力骤然下降,视力预后差异大。但目前聚焦于PCV合并VH的相关文献较少,因此研究和阐明PCV继发VH的治疗方法及预后具有重要的临床意义。目前临床上常选择手术干预,玻璃体切除术(pars plana vitrectomy,PPV)是临床上最常选择的一种术式。其他治疗方式包括玻璃体内注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)、眼内气体或硅油填充、眼内注射组织纤溶酶原激活剂(tissue plasminogen activator,tPA)和光动力疗法(photodynamic therapy,PDT)。PCV合并VH患者的视力预后决定因素是黄斑视功能的保留程度,也与年龄、术前视力、PCV病变部位、视网膜下出血量、视网膜脱离范围、基线黄斑中心厚度(central macular thickness,CMT)、是否出现术后并发症以及是否形成视网膜瘢痕等因素相关,目前也有研究发现视力预后与单核苷酸多态性(single nucleotide polymorphisms,SNP)相关。本文就PCV继发VH的临床特点、治疗及预后进行综述。
Polypoid choroidal vasculopathy (PCV) is a common fundus blinding disease in Asians. When PCV is associated with subretinal hemorrhage or vitreous hemorrhage (VH), patient's visual acuity decreases suddenly and the visual prognosis varies greatly. There are few relevant literatures focusing on VH secondary to PCV, so it is of great clinical significance to study and clarify the treatment methods and prognosis of VH secondary to PCV. At present, surgical intervention is often selected in clinical practice. Vitrectomy is the most commonly selected surgical procedure in clinical practice. The other treatment modalities include intravitreal injection of antivascular endothelial growth factor (VEGF), intraocular gas or silicone oil filling, intraocular injection of tissue plasminogen activator (tPA) and photodynamic therapy. The prognostic determinant of visual acuity in PCV
patients with VH is the degree of preservation of macular visual function. The prognostic is also related to age, preoperative visual acuity, PCV lesion location, amount of subretinal hemorrhage, extent of retinal detachment, baseline central macular thickness (CMT), postoperative complications and retinal scars. Recent studies also find that the prognosis of visual acuity is related to single nucleotide polymorphisms. This article reviews the clinical characteristics, treatment and visual prognosis of PCV associated with VH.
其他期刊
  • 眼科学报

    主管:中华人民共和国教育部
    主办:中山大学
    承办:中山大学中山眼科中心
    主编:林浩添
    主管:中华人民共和国教育部
    主办:中山大学
    浏览
  • Eye Science

    主管:中华人民共和国教育部
    主办:中山大学
    承办:中山大学中山眼科中心
    主编:林浩添
    主管:中华人民共和国教育部
    主办:中山大学
    浏览
推荐阅读
出版者信息
中山眼科



中山大学